Streptococcus intermedius cDNA and recombinant antigen

Streptococcus intermedius is a bacterium that can cause infections in humans, including brain abscesses, dental infections, and respiratory infections. One of the key components of this bacterium is its cell-surface antigen I-II, which plays a significant role in its pathogenesis.

Cell-Surface Antigen I-II: Structure and Function

Cell-surface antigen I-II is a protein complex that is composed of two proteins, antigen I and antigen II, that are anchored to the surface of Streptococcus intermedius. Antigen I is responsible for binding to host proteins, while antigen II is responsible for binding to bacterial cells. Together, these proteins facilitate the adherence of Streptococcus intermedius to host tissues and the formation of biofilms.

In addition to its role in adherence and biofilm formation, cell-surface antigen I-II has also been found to be important for the bacterium’s evasion of the host immune system. Studies have shown that antibodies against this antigen can enhance the clearance of Streptococcus intermedius infections, suggesting that it may be a potential target for the development of new treatments and vaccines.

The use of recombinant proteins/cDNA in academic research and therapeutic applications has skyrocketed. However, in heterologous expression systems, successful recombinant protein expression is dependent on a variety of factors, including codon preference, RNA secondary structure, and GC content. When compared to pre-optimization, more and more experimental results demonstrated that the expression level was dramatically increased, ranging from two to hundred times depending on the gene. Bioclone has created a proprietary technology platform that has resulted in the creation of over 6,000 artificially synthesized codon-optimized cDNA clones (cloned in E. coli expression Vector), which are ready for production of the recombinant proteins.

The cDNA and recombinant antigen from this organism have been used to develop diagnostic tests for the detection of S. intermedius infections. These tests are used to identify the presence of the organism in clinical specimens, as well as to determine the virulence of the strain present. The antigen can also be used to create vaccines that can be used to prevent S. intermedius infections. Additionally, the cDNA from S. intermedius can be used to study the genetic basis of the organism’s virulence and to identify potential drug targets for the treatment of S. intermedius infections.